c-MET Protein (AA 25-932) (His tag,AVI tag,Biotin)

N° du produit ABIN3137684

Détail du produit

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 25-932

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette c-MET protéine est marqué à la His tag,AVI tag,Biotin.

Marque: MABSol®,PrecisionAvi

Séquence: AA 25-932

Specificité: Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Attributs du produit: This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 104.3 kDa. The protein migrates as 40-45 kDa α subunit and 75 kDa β subunit under reducing (R) condition (SDS-PAGE) due to glycosylation.

Pureté: >90 % as determined by SDS-PAGE.

niveau d'endotoxine: Less than 1.0 EU per μg by the LAL method.

Information d'application

Commentaires:

Ready-to-use AvitagTM biotinylated protein:
The product is exclusively produced using the AvitagTM technology. Briefly, a unique 15 amino acid peptide, the Avi tag, is introduced into the recombinant protein during expression vector construction. The single lysine residue in the Avi tag is enzymatically biotinylated by the E. Coli biotin ligase BirA.

This single-point enzymatic labeling technique brings many advantages for commonly used binding assays. The biotinylation happens on the lysine residue of Avi tag, and therefore does NOT interfere with the target protein's natural binding activities. In addition, when immobilized on an avidin-coated surface, the protein orientation is uniform because the position of the Avi tag in the protein is precisely controlled.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: PBS, pH 7.4

Conseil sur la manipulation: Please avoid repeated freeze-thaw cycles.

Stock: -20 °C

Référence

Gong, Ren, Wu, Wu, Wu: "Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets." dans: mAbs, Vol. 9, Issue 7, pp. 1118-1128, (2018) (PubMed).

Détail du antigène

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: HGFR (MET Produits)

Synonymes: AUTS9 Protein, HGFR Protein, RCCP2 Protein, c-Met Protein, AI838057 Protein, HGF Protein, Par4 Protein, Hgfr Protein, c-met Protein, MET Protein, C-MET Protein, met Protein, met-A Protein, MET proto-oncogene, receptor tyrosine kinase Protein, met proto-oncogene Protein, MET proto-oncogene, receptor tyrosine kinase L homeolog Protein, MET Protein, Met Protein, met.L Protein

Sujet: Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.

Poids moléculaire: 104.3 kDa

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor